

**STERLING BIOTECH LIMITED**

Regd. Office: 43, Atlanta Building, Nariman Point, Mumbai - 400 021

CIN : L51900MH1985PLC035738

**UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE SECOND QUARTER ENDED 30 JUNE 2015**

**PART I**

(Rs. in Lacs)

Sr. No.	Particulars	Three Months ended			Six Months ended		Twelve Months ended
		30/06/2015	31/03/2015	30/06/2014	30/06/2015	30/06/2014	31/12/2014
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	<b>Income from Operations</b>						
	a) Net Sales/Income from Operations	11,689.57	10,062.99	18,435.81	21,752.56	37,257.17	66,695.07
	b) Other Operating Income	118.69	142.53	130.39	261.22	192.37	368.20
	<b>c) Total Income from Operations</b>	<b>11,808.26</b>	<b>10,205.52</b>	<b>18,566.20</b>	<b>22,013.78</b>	<b>37,449.54</b>	<b>67,063.27</b>
2	<b>Expenses</b>						
	a) Cost of materials consumed	7,971.45	17,329.82	22,450.06	25,301.27	31,738.10	61,783.87
	b) Purchase of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(347.48)	(10,548.63)	(9,851.03)	(10,896.11)	(6,489.23)	(15,232.62)
	d) Employee benefits expense	1,345.48	1,226.99	1,280.61	2,572.47	2,660.58	5,167.27
	e) Depreciation and amortization expense	7,017.02	7,049.55	6,405.76	14,066.57	12,794.62	27,657.43
	f) Other Expenses	702.51	881.99	890.15	1,584.50	2,069.68	3,852.80
	<b>g) Total Expenses</b>	<b>16,688.98</b>	<b>15,939.72</b>	<b>21,175.55</b>	<b>32,628.70</b>	<b>42,773.75</b>	<b>83,228.75</b>
3	<b>Profit / (Loss) from Operations before Other Income and finance Costs (1-2)</b>	<b>(4,880.72)</b>	<b>(5,734.20)</b>	<b>(2,609.35)</b>	<b>(10,614.92)</b>	<b>(5,324.21)</b>	<b>(16,165.48)</b>
4	Other Income	0.00	0.00	0.00	0.00	0.00	0.00
5	<b>Profit / (Loss) from Ordinary activities before finance costs (3+4)</b>	<b>(4,880.72)</b>	<b>(5,734.20)</b>	<b>(2,609.35)</b>	<b>(10,614.92)</b>	<b>(5,324.21)</b>	<b>(16,165.48)</b>
6	Finance Costs	8,217.04	7,639.36	12,751.70	15,856.40	25,332.80	46,950.57
7	<b>Profit / (Loss) from Ordinary Activities after finance costs but before tax (5-6)</b>	<b>(13,097.76)</b>	<b>(13,373.56)</b>	<b>(15,361.05)</b>	<b>(26,471.32)</b>	<b>(30,657.01)</b>	<b>(63,116.05)</b>
8	Tax expense						
	a) Current	0.00	0.00	0.00	0.00	0.00	0.00
	b) Deferred	(4,250.00)	(4,339.00)	(4,984.00)	(8,589.00)	(9,947.00)	(20,478.00)
	c) Total	(4,250.00)	(4,339.00)	(4,984.00)	(8,589.00)	(9,947.00)	(20,478.00)
9	<b>Net Profit / (Loss) from Ordinary Activities after tax (7-8)</b>	<b>(8,847.76)</b>	<b>(9,034.56)</b>	<b>(10,377.05)</b>	<b>(17,882.32)</b>	<b>(20,710.01)</b>	<b>(42,638.05)</b>
10	Extraordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
11	<b>Net Profit / (Loss) for the period (9+10)</b>	<b>(8,847.76)</b>	<b>(9,034.56)</b>	<b>(10,377.05)</b>	<b>(17,882.32)</b>	<b>(20,710.01)</b>	<b>(42,638.05)</b>
12	Prior year adjustment	0.00	0.00	(650.00)	0.00	(650.00)	(3,132.47)
13	<b>Profit available for appropriation</b>	<b>(8,847.76)</b>	<b>(9,034.56)</b>	<b>(11,027.05)</b>	<b>(17,882.32)</b>	<b>(21,360.01)</b>	<b>(45,770.52)</b>
14	Paid-up equity share capital (Face Value of Re.1/- per share)	2,720.48	2,720.48	2,679.96	2,720.48	2,679.96	2,720.48
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year						101,026.03
16.i	Earnings Per Equity Share (EPS) (before extraordinary items) (F.V. of Re.1/- each) (not annualised)						
	a) Basic	(3.25)	(3.32)	(3.87)	(6.57)	(7.73)	(15.67)
	b) Diluted	(2.04)	(2.09)	(2.40)	(4.13)	(4.78)	(9.85)
16.ii	Earnings Per Equity Share (EPS) (after extraordinary items) (F.V. of Re.1/- each) (not annualised)						
	a) Basic	(3.25)	(3.32)	(4.11)	(6.57)	(7.97)	(16.82)
	b) Diluted	(2.04)	(2.09)	(2.55)	(4.13)	(4.93)	(10.57)
17	Debt Service Coverage Ratio (DSCR)	0.02	0.01	0.02	0.03	0.04	0.07
18	Interest Service Coverage Ratio (ISCR)	0.26	0.17	0.25	0.22	0.27	0.18

**STERLING BIOTECH LIMITED**  
 Regd. Office: 43, Atlanta Building, Nariman Point, Mumbai - 400 021  
 CIN : L51900MH1985PLC035738  
 Select Information for the Quarter ended 30 June 2015

**PART II**

Sr. No.	Particulars	Three Months ended			Six Months ended		Twelve Months ended
		30/06/2015	31/03/2015	30/06/2014	30/06/2015	30/06/2014	31/12/2014
<b>A</b>	<b>PARTICULARS OF SHAREHOLDING</b>						
1	Public Shareholding						
	- Number of Equity shares	135,545,090	135,545,090	131,861,090	135,545,090	131,861,090	135,545,090
	- Percentage of shareholding	49.82%	49.82%	49.20%	49.82%	49.20%	49.82%
2	Promoters and Promoter Group Shareholding						
	a) Pledged/Encumbered						
	Number of Equity shares	50,816,835	50,816,835	50,816,835	50,816,835	50,816,835	50,816,835
	Percentage of Shares (as a % of the total Equity shareholding of promoter and promoter group)	55.94%	55.94%	55.94%	55.94%	55.94%	55.94%
	Percentage of shares (as a % of the total Equity share capital of the Company)	18.68%	18.68%	18.96%	18.68%	18.96%	18.68%
	b) Non-encumbered						
	Number of Equity shares	40,023,300	40,023,300	40,023,300	40,023,300	40,023,300	40,023,300
	Percentage of Shares (as a % of the total Equity shareholding of promoter and promoter group)	44.06%	44.06%	44.06%	44.06%	44.06%	44.06%
	Percentage of shares (as a % of the total Equity share capital of the Company)	14.71%	14.71%	14.93%	14.71%	14.93%	14.71%

Sr. No.	Particulars	Quarter ended 30/06/2015
<b>B</b>	<b>INVESTOR COMPLAINTS</b>	
	Pending at the beginning of the Quarter	0
	Received during the quarter	1
	Disposed of during the quarter	1
	Remaining unresolved at the end of the quarter	0

**STANDALONE STATEMENT OF ASSETS AND LIABILITIES**

(Rs. In Lacs)

Sr. No.	Particulars	STANDALONE		
		Six Months Ended		Year ended
		30/06/2015	30/06/2014	31/12/2014
		Unaudited	Unaudited	Audited
<b>A</b>	<b>EQUITY AND LIABILITIES</b>			
1	<b>SHAREHOLDERS' FUND</b>			
	a) Share Capital	176,491.72	2,679.96	153,403.14
	b) Reserves and Surplus	83,143.71	123,045.87	101,026.03
	c) Money received against share warrants	0.00	0.00	0.00
	<b>Sub - total Shareholders' Funds</b>	<b>259,635.43</b>	<b>125,725.83</b>	<b>254,429.17</b>
2	Share Application money pending allotment	0.00	84,469.85	0.00
3	<b>Non-current liabilities</b>			
	a) Long-term borrowings	232,632.80	197,024.10	186,114.64
	b) Deferred tax liabilities (net)	0.00	0.00	0.00
	c) Other long-term liabilities	0.00	0.00	0.00
	d) Long-term provisions	0.00	0.00	0.00
	<b>Sub-total - Non-current liabilities</b>	<b>232,632.80</b>	<b>197,024.10</b>	<b>186,114.64</b>
4	<b>Current liabilities</b>			
	a) Short-term borrowings	103,536.77	125,766.16	118,171.45
	b) Trade payables	2,626.95	1,823.68	2,469.06
	c) Other current liabilities	131,193.76	181,006.20	160,069.08
	d) Short-term provisions	0.00	0.00	0.00
	<b>Sub-total - Current liabilities</b>	<b>237,357.48</b>	<b>308,596.04</b>	<b>280,709.59</b>
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>729,625.71</b>	<b>715,815.82</b>	<b>721,253.40</b>
<b>B</b>	<b>ASSETS</b>			
1	<b>Non-current assets</b>			
	a) Fixed assets	546,919.71	538,438.37	554,396.88
	b) Goodwill on consolidation	0.00	0.00	0.00
	c) Non-current investments	16,890.75	16,890.75	16,890.75
	d) Deferred tax assets (net)	33,625.99	14,505.99	25,036.99
	e) Long-term loans and advances	0.00	0.00	0.00
	f) Other non-current assets	17,809.46	0.00	18,857.07
	<b>Sub-total - Non-current assets</b>	<b>615,245.91</b>	<b>569,835.11</b>	<b>615,181.69</b>
2	<b>Current assets</b>			
	a) Current investments	0.00	0.00	0.00
	b) Inventories	73,416.96	85,582.58	63,456.54
	c) Trade receivables	5,047.91	36,489.60	18,055.92
	d) Cash and cash equivalents	1,679.27	2,008.65	1,765.92
	e) Short-term loans and advances	34,235.66	21,899.88	22,793.33
	f) Other current assets	0.00	0.00	0.00
	<b>Sub-total - Current assets</b>	<b>114,379.80</b>	<b>145,980.71</b>	<b>106,071.71</b>
	<b>TOTAL - ASSETS</b>	<b>729,625.71</b>	<b>715,815.82</b>	<b>721,253.40</b>

**STERLING BIOTECH LIMITED**

**Regd. Office: 43, Atlanta Building, Nariman Point, Mumbai - 400 021**

**CIN : L51900MH1985PLC035738**

**UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE SECOND QUARTER ENDED 30 JUNE 2015**

**Notes:**

- 1 The company's operations fall under single segment hence segment reporting as defined in Accounting Standard 17 is not applicable.
- 2 The above Financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors in its meeting held on 14 August, 2015.
- 3 The Statutory Auditors have carried out a limited review of the financial results for the quarter ended on 30 June 2015.
- 4 The Company has Overseas Subsidiaries and there are no business operations in the subsidiary companies.
- 5 Previous period figures have been regrouped/reclassified, wherever necessary.

**For and on Behalf of  
STERLING BIOTECH LIMITED**

Place : Mumbai  
Date : 14 August 2015.

**Chetan J. Sandesara  
Joint Managing Director**